A new tablet version of one of the world’s most popular weight-loss medications has been approved for use in the UK, potentially opening the door to greater access for patients seeking support with obesity and weight management. The treatment, developed by Novo Nordisk, contains semaglutide — the same active ingredient found in the injectable Wegovy […]
